BWAY Brainsway

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of . The National Alliance on Mental Illness (NAMI) organizes NAMIWalks Your Way events around the country each year to increase mental health awareness, build community, and help raise funds for programs. The Silicon Valley Walk will be Saturday, October 1, 2022.



“I am honored to be part of this extremely important event, which aligns with BrainsWay’s goal of raising awareness about mental illness and increasing access to mental health resources. I am inspired by the work NAMI does for mental health around the country, and I am looking forward to joining forces at the NAMI Silicon Valley walk,” said Dr. von Jako.

He added, “NAMI Walks are wonderful opportunities to meet patients, families, and providers to hear their stories, and work together for a brighter future. I encourage everyone in Silicon Valley to participate in the Walk, taking steps as a community to improve mental healthcare for all.”

Rovina Nimbalkar, Executive Director of NAMI Santa Clara County, said, “We are honored to have Christopher von Jako as our honorary chair for NAMIWalks Silicon Valley and we are excited about our collaboration with BrainsWay. NAMIWalks Silicon Valley is our biggest fundraiser, and after two years we are going to walk in person. The last two years have been particularly difficult for people with a mental health diagnosis, and we walk to honor them and to create awareness for mental illness.”

The October 1 event will be in San Jose’s History Park from 9:00am – 1:00pm PST. In addition to Dr. von Jako, members of the mental health team of the San Francisco Giants will speak at the event, including Drew Robinson, Dr. Emily Payette, Minor League Mental Health Coordinator, and Dr. Shana Alexander, Director of Mental Health, Wellness, and EAP. NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness.

Click to register for the event.



About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Media Contact:

Meghan Laska

610-212-0125

 

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989



EN
20/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE

BrainsWay Reports First Quarter 2025 Financial Results and Operational...

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net number of Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Company is reiterating its full-year 2025 financial guidance, including revenue of $49 to $51 million, ope...

 PRESS RELEASE

BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Associ...

BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles Exhibit Booth Demonstrations and Participation in Expert Master Course Highlight BrainsWay’s Expanding Role in Psychiatric Care BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California....

 PRESS RELEASE

BrainsWay to Report First Quarter 2025 Financial Results on May 13, 20...

BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025 BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the...

 PRESS RELEASE

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results ...

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWS...

 PRESS RELEASE

BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech...

BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference BURLINGTON, Mass. and JERUSALEM, March 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference at 9:20 AM EST on March 18, 2025. A live webcast of the presentation will be available on the Events & News – Presentations page of the Co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch